Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment is a research paper published in Pharmaceutics (2022). On theSindex it has a DataRank of 0. It has been cited 41 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH NCI
Grant: P01CA250972
NIH NCI
Grant: F30CA268780
NIH NCI
Grant: T32GM140935
NIH HHS
Grant: DP5 OD024576
National Institutes of Health
Grant: 5T32GM140935-02
Integrated Training For Physician-Scientists
National Institutes of Health
Grant: 5F30CA268780-04
Targeted radionuclide therapy for tumor immunomodulation and enhancing immunotherapy response
National Institutes of Health
Grant: 5P01CA250972-02
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response
FWCI
4.17
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals